摘要
抗体药物偶联物(ADCs)是具有单克隆抗体的精确靶向能力和化疗药物的强效细胞毒性作用的一类抗肿瘤药物。新一代ADCs的问世,给乳腺癌患者带来了生存获益。目前,已有ADCs获批用于人表皮生长因子受体2(HER-2)阳性乳腺癌的治疗,同时还有多种ADCs正在临床试验中。然而,随着ADCs在临床中的应用,耐药问题逐渐出现。文章将对ADCs的作用机制、抗HER-2 ADCs在乳腺癌的疗效概况及耐药机制进行总结。
Antibody drug conjugates(ADCs)are a class of anti-tumor drugs that combines the precise targeting ability of monoclonal antibodies with the potent cytotoxic effects of chemotherapy drugs.The advent of a new generation of ADCs has brought survival benefits to breast cancer patients.ADCs have been currently approved for treating human epidermal growth factor receptor-2(HER-2)positive breast cancer,and many kinds of ADCs are being evaluated in clinical trials.However,with the increasing use of ADCs in clinical practice,drug resistance issues have gradually emerged.This article summarizes the mechanism of action of ADCs,as well as the efficacy and mechanism of drug resistance of anti-HER-2 ADCs in breast cancer.
作者
韩兆雪
孙涛
徐君南
李晓睿
马艺文
Han Zhaoxue;Sun Tao;Xu Junnan;Li Xiaorui;Ma Yiwen(The First Department of Breast Oncology,Cancer Hospital of China Medical University,Cancer Hospital of Dalian University of Technology,Liaoning Cancer Hospital and Institute,Shenyang 110042,China)
出处
《中国肿瘤临床与康复》
2024年第3期133-142,共10页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
沈阳市乳腺癌临床医学研究中心课题(2020-48-3-1)
沈阳市科学技术计划公共卫生研发专项(22-321-31-04)
辽宁省肿瘤医院-大连理工大学“医-工交叉研究基金”项目(202229,202230)。
关键词
乳腺肿瘤
抗体药物偶联物
人表皮生长因子受体2
耐药
Breast neoplasms
Antibody drug conjugates
Human epidermal growth factor receptor-2
Drug resistance
